Is there really a “best month” to invest? A closer look at Nifty’s monthly moves shows volatility is the norm—and timing the market is far less predictable than it seems. Time in the market matters more than timing it. See the pattern.

One IPO. Two businesses. One big dependency. @PowericaLimited is priced at ~30x earnings. But how much of the business does it really control? Read our full take on the valuation: tinyurl.com/psuf6wm6

Market pain is widespread this year. Percentage of companies with negative YTD returns: • Large cap: 61.4% • Mid cap: 72.7% • Small cap: 81.8% Short-term declines are uncomfortable, but staying invested and focused on the long term often matters more than timing the market. @ValueResearch

Tens of thousands of crores wiped out of Indian IT stocks in two weeks. One AI demo. That’s all it took. But here’s the thing about panic: it doesn’t read balance sheets. Read our analysis - vro.in/s227923

CleanMax Enviro’s ₹3,100 crore IPO is here, but the real question is beyond the issue size. Market leader in C&I renewables with strong growth visibility. Yet profits are recent, debt is high, and valuations are steep. Full analysis: vro.in/23995a

Union Budget 2026 is out. Headlines grab attention, but numbers tell the truth. Revenue. Spending. Signals for the economy. Here’s a structured look at what Budget 2026 really says. 👇

Bharat Coking Coal Limited is heading to the market with a ₹1,071 crore IPO- and it’s worth looking beyond the headline size. India’s largest producer of coking coal brings scale, dominant domestic share, and a critical role in the steel supply chain. But the business also comes with concentration risks, from region-specific operations to dependence on a single product. Before deciding whether this IPO fits into your portfolio, it helps to weigh the strengths, the constraints, and the valuation- without rushing. Full analysis by Value Research Stock Advisor. @ValueResearch

ICICI Prudential AMC is heading to the market with a ₹10,603 crore IPO- and it’s worth looking beyond the headline size. India’s largest active fund house brings scale, strong equity and hybrid leadership, and robust profitability. But like all AMCs, its fortunes remain closely tied to market cycles. Before deciding whether this fits into your portfolio, it helps to weigh the strengths, the sensitivities, and the valuation- without hurry. Full analysis by Value Research Stock Advisor. @ValueResearch

Park Medi World is coming to the public markets with a ₹920 crore IPO. Before you decide whether it deserves your money, here’s a clear breakdown of what works, what doesn’t, and what the numbers reveal. Full analysis by Value Research Stock Advisor. @ValueResearch

CORONA Remedies is coming to the public markets with a ₹655 crore IPO. Before you decide whether it deserves your money, here’s a clear breakdown of what works, what doesn’t, and what the numbers reveal. Full analysis by Value Research Stock Advisor. @ValueResearch

Wakefit Innovations is coming to the public markets with a ₹1,289 crore IPO. Before you decide whether it deserves your money, here’s a clear breakdown of what works, what doesn’t, and what the numbers reveal. Full analysis by Value Research Stock Advisor. @ValueResearch